武汉金唯科生物科技

King-Viko is a clinical-stage biotechnology company based in Wuhan, China, specializing in the development of adeno-associated virus (AAV) mediated gene therapies. Founded by Professor Xiao Xiao, a pioneer in the AAV field, the company leverages a proprietary rAAV vector platform to target a wide range of genetic and chronic diseases. Its lead program, JWK001, is currently in clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). King-Viko's pipeline also includes candidates for hemophilia, lysosomal storage disorders, and neuromuscular diseases. The company operates integrated R&D and GMP manufacturing facilities to support its transition from discovery to commercialization.